Provided by
| Consensus (mean) in EUR million | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 E |
|---|---|---|---|---|---|
| Orders received | 1,281 | 1,092 | 1,373 | 1,408 | 1,292 |
| - Biomaterial Solutions and Services | 908.0 | 693.0 | 994.0 | 1,009.0 | 853.7 |
| - Process Performance Solutions | 372.0 | 400.0 | 379.0 | 399.0 | 438.3 |
| Net sales | 1,477 | 1,244 | 1,315 | 1,360 | 1,467 |
| - Biomaterial Solutions and Services | 1,067.0 | 904.0 | 945.0 | 952.0 | 994.2 |
| - Process Performance Solutions | 410.0 | 341.0 | 370.0 | 408.0 | 476.3 |
| Comparable EBITA | 196 | 114 | 152 | 169 | 199 |
| - Biomaterial Solutions and Services | 123.0 | 64.0 | 98.0 | 102.0 | 116.5 |
| - Process Performance Solutions | 90.0 | 63.0 | 69.0 | 82.0 | 96.2 |
| Comparable EBITA Margin (%) | 13.3% | 9.2% | 11.5% | 12.4% | 13.5% |
| - Biomaterial Solns. and Servs. | 11.6% | 7.1% | 10.4% | 10.7% | 11.7% |
| - Process Perf. Solns. | 21.9% | 18.5% | 18.7% | 20.2% | 20.3% |
| Reported EPS | 0.57 | 0.19 | 0.40 | 0.38 | 0.63 |